Terns Pharmaceuticals, Inc.
TERN
Kedudukan dalam Saham
#3570
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Harga Saham
$52.95
Disegerakkan terakhir: 2026-05-15
Modal Pasaran
$4.77B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
529.61%
Negara
US
Perdagangan Terns Pharmaceuticals, Inc. (TERN)
Kategori
Healthcare
Bilangan saham terbitan bagi Terns Pharmaceuticals, Inc. (TERN)
Bilangan saham terbitan setakat December 2025: 93.17M
Menurut laporan kewangan terkini dan harga saham Terns Pharmaceuticals, Inc., bilangan saham terbitan semasa ialah 93.17M. Pada akhir December 2023, syarikat mempunyai 71.26M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Terns Pharmaceuticals, Inc. (TERN) dari 2018 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 93.17M | 17.18% |
| 2024 | 79.51M | 11.57% |
| 2023 | 71.26M | 97.76% |
| 2022 | 36.03M | 42.60% |
| 2021 | 25.27M | 0.57% |
| 2020 | 25.13M | 0.11% |
| 2019 | 25.10M | 4.69% |
| 2018 | 23.97M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 172.52% |
US
|
|
| 396.00M | 325.05% |
US
|
|
| 478.91M | 414.04% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -33.25% |
NL
|
